Latest Viking Therapeutics News & Updates

See the latest news and media coverage for Viking Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Viking Therapeutics

Clinical-stage biotechnology company developing therapies for obesity and metabolic diseases

vikingtherapeutics.com

Headquarters: San Diego, United States
Founded year: 2012
Company type: Public company
Number of employees: 70–200
Industry: Pharmaceuticals

Last updated October 28

Latest news about Viking Therapeutics

In short: Viking Therapeutics reported a wider Q3 loss as it advanced oral VK2735 into Phase 3.

Company announcements

October 28 Viking Therapeutics

Viking Therapeutics reports Q3 2026 financials and pipeline updates

The company raised $960 million cash while announcing Phase 3 oral VK2735 trials and positive maintenance dosing data. Net loss widened to $183.2 million due to higher R&D costs.

October 14 Viking Therapeutics

Viking Therapeutics initiates Phase 3 oral VK2735 obesity trials

The SUNRISE program evaluates oral VK2735 in adults with and without type 2 diabetes for 68 weeks to assess weight loss efficacy

September 28 Viking Therapeutics

Viking Therapeutics closes $575 million stock and notes offerings

Proceeds fund clinical development of VK2735 and VK3019 for obesity and metabolic disorders.

September 23 Viking Therapeutics

Viking Therapeutics announces proposed stock and note offerings

The company plans to raise $400 million through common stock and convertible senior notes due 2032 to fund clinical development of VK2735 and general corporate purposes.

Media coverage

October 20 Yahoo Finance

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its...

October 18 MSN

Viking Therapeutics just raised $575 million. Here's what it means for the obesity stock's next chapter.

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

October 10 MSN

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

October 5 Fox 44 News

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

(Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of...

Never miss news about Viking Therapeutics

Track Viking Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Viking Therapeutics competitors & trending companies

Browse news for competitors to Viking Therapeutics and other trending companies.